Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) has been ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Novo Nordisk has beaten Wall Street's revenue estimates ... while its competitor has only one [Alhemo]. Eli Lilly's R&D portfolio includes 77 projects, 22 of which are in Phase 3.

Novo Nordisk's anti-TFPI antibody concizumab has ... Concizumab – which has the trade name Alhemo – is already approved in other markets, including Japan, Australia, and Switzerland, but ...

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) bleeding prevention injection for patients with rare clotting disorders ...

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.

The fitusiran approval comes just months after the FDA approved concizumab-mtci (Alhemo; Novo Nordisk) as the first subcutaneous prophylaxis for hemophilia A and B with inhibitors. 3 1.

Qfitlia also holds a convenience edge over two of the most recently approved hemophilia drugs—Novo Nordisk’s Alhemo and Pfizer’s Hympavzi. Though both can be used by hemophilia A and B ...

Qfitlia’s monthly regimen already gives it an advantage over Novo Nordisk’s daily Alhemo (concizumab) and Pfizer’s weekly Hympavzi (marstacimab), two of the most recent drugs approved by the ...

The first-in-class treatment is given bimonthly for people with hemophilia A or B, with or without inhibitors, compared with treatments such as Pfizer's weekly injection Hympavzi and Novo Nordisk's ...

compared with treatments such as Pfizer's weekly injection Hympavzi and Novo Nordisk's daily Alhemo. "If you can take a drug every other month, that's also an incredible simplification and ...